Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Genmab A/S (GMAB)
NASDAQ:GMAB
Holding GMAB?
Track your performance easily
Earnings Data
Report Date
Feb 12, 2025During Market Hours Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
$0.36Last Year’s EPS
$0.14Same Quarter Last Year
Moderate Buy
Based on 7 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 06, 2024
|% Change Since: -10.73%
|Next Earnings Date:Feb 12, 2025
Earnings Call Sentiment|Positive
Genmab demonstrated a strong financial performance in Q1 2024, with significant revenue growth and successful product launches. However, increased operational expenses and ongoing regulatory challenges present potential obstacles.Company Guidance
During Genmab's Q1 2024 earnings call, the company highlighted its robust financial performance and strategic initiatives that are expected to drive future growth. Key metrics included a 42% increase in recurring revenues, driven by strong royalties from DARZALEX ($2.7 billion in net sales, up 19% year-over-year) and Kesimpta ($637 million, up 66% year-over-year). EPKINLY contributed $54 million in net sales, showing strong uptake in the U.S. and Japan. Tivdak also performed well, generating $27 million in sales. The company reported a revenue of over DKK 4.1 billion and an operating profit exceeding DKK 800 million, reflecting a growth of over 90% compared to the previous year. Genmab is on track to meet its 2024 financial targets, excluding potential impacts from the proposed acquisition of ProfoundBio. The acquisition is expected to enhance Genmab's pipeline with Rina-S, a promising asset in ovarian cancer, and is anticipated to close in the first half of 2024, pending regulatory approval.Strong Revenue Growth
Genmab reported over DKK 4.1 billion in Q1 revenue, marking a 46% increase year-over-year, driven by strong royalties from DARZALEX, Kesimpta, and other medicines, as well as net product sales for EPKINLY.
Successful Product Launches and Approvals
EPKINLY launched successfully in the U.S., Europe, and Japan, with Tivdak receiving full FDA approval for cervical cancer. These products contributed 27% of total revenue growth in Q1.
DARZALEX and Kesimpta Performance
DARZALEX achieved nearly USD 2.7 billion in net sales, a 19% year-over-year growth, while Kesimpta saw a 66% increase with USD 637 million in Q1.
Acquisition to Enhance Oncology Pipeline
The proposed acquisition of ProfoundBio, including its lead asset Rina-S, is expected to strengthen Genmab's ADC capabilities and pipeline, with potential approval anticipated in 2027.
---
GMAB Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
GMAB Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 06, 2024 | $22.75 | $22.33 | -1.85% |
| Aug 08, 2024 | $26.46 | $27.07 | +2.31% |
| May 02, 2024 | $28.75 | $27.72 | -3.58% |
| Feb 14, 2024 | $26.43 | $27.59 | +4.39% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Genmab A/S (GMAB) report earnings?
Genmab A/S (GMAB) is schdueled to report earning on Feb 12, 2025, During Market Hours Not Confirmed.
What is Genmab A/S (GMAB) earnings time?
Genmab A/S (GMAB) earnings time is at Feb 12, 2025, During Market Hours Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is GMAB EPS forecast?
GMAB EPS forecast for the fiscal quarter 2024 (Q4) is $0.36.
---